🇨🇦 XZP-5610 Tablet for "Part C2" in Canada

XZP-5610 Tablet for "Part C2" (XZP-5610 Tablet for "Part C2") regulatory status in Canada.

Marketing authorisation

XZP-5610 Tablet for "Part C2" in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is XZP-5610 Tablet for "Part C2" approved in Canada?

Yes. Health Canada has authorised it.

Who is the marketing authorisation holder for XZP-5610 Tablet for "Part C2" in Canada?

Xuanzhu Biopharmaceutical Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.